PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $166,000 | -22.1% | 26,500 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $213,000 | +7.6% | 26,500 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $198,000 | +25.3% | 26,500 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $158,000 | -19.0% | 26,500 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $195,000 | +8.3% | 26,500 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $180,000 | -33.3% | 26,500 | +10.4% | 0.00% | -50.0% |
| Q1 2017 | $270,000 | +30.4% | 24,000 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $207,000 | +36.2% | 24,000 | 0.0% | 0.00% | +100.0% |
| Q3 2016 | $152,000 | +46.2% | 24,000 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $104,000 | -29.3% | 24,000 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $147,000 | +7.3% | 24,000 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $137,000 | -23.5% | 24,000 | 0.0% | 0.00% | – |
| Q2 2015 | $179,000 | +25.2% | 24,000 | 0.0% | 0.00% | – |
| Q1 2015 | $143,000 | +58.9% | 24,000 | +100.0% | 0.00% | – |
| Q4 2014 | $90,000 | +45.2% | 12,000 | 0.0% | 0.00% | – |
| Q3 2014 | $62,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |